Why Batch Release Delays Are Usually a Review Problem, Not a Manufacturing One
When a batch release slips, the first place most teams look is the production floor. Was there a deviation on the line? A supply issue? An equipment fault?
Often the answer is none of the above. The batch was manufactured on schedule. It sat waiting for review.
Batch record review is where release timelines quietly unravel. It rarely makes the incident report, because nothing went wrong in the technical sense. The record simply took longer to work through than the schedule assumed, and by the time that becomes visible, the release date has already moved.
This article looks at why review, not manufacturing, is usually the real constraint on batch release, and what a structured review model does differently.
Where the time actually goes
A batch record is not one document. For anything beyond the simplest product, it is a stack of interlinked records: manufacturing instructions, in-process checks, analytical results, equipment logs, deviation reports, and change controls, all of which need to reconcile before a QP can certify the batch.
Reviewing that stack properly takes time, and the time required does not scale in a straight line. A batch with two minor deviations takes longer than twice as long to review as a clean batch, because each deviation has to be traced through its own investigation, impact assessment, and closure evidence before the reviewer can sign off the record as a whole.
For advanced therapies and other data-intensive products, the volume alone can be the constraint. Reviewing a single complex AAV or cell therapy batch can mean working through tens of thousands of pages of manufacturing and analytical data. That is not a task a generalist QA function can absorb alongside its normal workload without something else slipping.
Where batch review bottlenecks usually sit
• Deviations and OOS results that need full investigation before the record can close
• Data-heavy products where the record itself runs to thousands of pages
• Reviewer capacity that was sized for steady-state volume, not launch or scale-up peaks
• Handoffs between production, QA and QP that each add a queue
• Inconsistent review standards when workload is split across multiple reviewers under pressure
The cost of a slow review is easy to underestimate
A batch sitting in review is a batch that is not generating revenue, not meeting a supply commitment, and in many cases, not reaching a patient who is waiting for it.
For commercial products, a review backlog shows up as missed shipment windows and strained distributor relationships. For clinical supply, it can mean a site running short of investigational product, a dosing visit rescheduled, or a trial timeline absorbing a delay that has nothing to do with the science.
The knock-on effects tend to compound. A late batch pushes the next batch's review into an already full queue. Expedited freight gets booked to recover time lost in review, adding cost to offset a delay that had nothing to do with logistics. None of this shows up cleanly against the release date. It shows up as pressure everywhere else.
TDP provides GMP Batch Review as a Service, giving you QP-led review capacity that flexes with your batch volume, not a fixed headcount sized for an average month.
It gets worse as products get more complex
The batch review burden is not distributed evenly across a portfolio. A well-established small-molecule product with a mature, stable process generates a batch record that a reviewer can move through quickly, because the pattern is familiar and the deviations, when they happen, are usually variations on ones seen before.
Advanced therapies do not behave that way. Cell and gene therapy batches are frequently manufactured at small scale for named patients, on tight clinical timelines, with analytical packages that run far beyond what a conventional product would generate. Every batch can look different from the last, because the manufacturing history, the raw material lots, and sometimes the process itself are still evolving alongside early commercial or late clinical use.
That combination, high stakes, high data volume, and low process maturity, is exactly where review capacity gets stretched thinnest, and exactly where the cost of a delay is hardest to absorb. A missed release window on a rare disease therapy is not simply a commercial inconvenience. It is a patient who does not get their dose on schedule.
Why this is a review problem, not a manufacturing one
It is worth being precise about what is actually happening here, because the fix depends on it.
1. Review capacity is usually sized for the average, not the peak. Most in-house QA functions are resourced for steady-state batch volume. A launch, a scale-up, or a run of batches with deviations pushes demand above that baseline, and there is no slack to absorb it without something else being deprioritised.
2. Specialist products need specialist reviewers. A generalist QA reviewer can work through a straightforward small-molecule batch record efficiently. A record for a gene therapy, biologic, or complex combination product often needs someone who has reviewed that type of data before, or the review itself becomes the bottleneck while the reviewer works out what they are looking at.
3. Deviations multiply review time disproportionately. Each deviation adds its own investigation trail to trace, cross-reference, and sign off. A batch with several open deviations can take several times longer to review than a clean one, not a proportionate amount longer.
4. Inconsistent standards create rework. When review gets split across multiple people under time pressure, interpretation of what counts as acceptable evidence can drift. That inconsistency surfaces later, in QP queries, in audit findings, or in an inspector asking why two similar deviations were assessed differently.
5. The backlog is invisible until it is not. Review delays build quietly. There is no single moment where the problem becomes obvious, until a launch date or a supply commitment depends on a batch that is still sitting in the queue.
What a structured review model looks like
The fix is not simply adding headcount. It is building review capacity that can flex to the batch, rather than forcing the batch to fit a fixed capacity.
A structured, outsourced batch review model gives you access to senior reviewers, often QP-led, who can absorb a surge in volume, work through complex or data-heavy records at pace, and apply a consistent standard across every batch reviewed, regardless of who is doing the reviewing that week.
Done well, this is not a detached service sitting outside your quality system. The review team works within your procedures, against your specifications, and reports into your QP for certification. The difference is capacity and specialism, not a change in who is ultimately accountable for the batch.
What to look for in a review partner
• Reviewers with direct experience of your product type, not generalist QA cover
• Capacity that can scale up for a launch or a backlog without a lengthy onboarding period
• A track record with complex or data-intensive batch records, not just routine ones
• Clear reporting lines into your QP, so accountability for certification stays where it belongs
• Consistent turnaround times, even when deviations are involved
TDP has reviewed batches ranging from routine releases to complex AAV records running to over 70GB of data, resolving major and critical deviations without missing the release window.
Building capacity without overbuilding headcount
The instinctive fix is to hire. It is rarely the right one.
Hiring permanent reviewers to cover peak demand means carrying that cost through every quiet month in between, and specialist reviewers for advanced therapies are neither quick to find nor cheap to retain once a launch or scale-up phase has passed and volumes settle back down.
Hiring to average demand leaves you exactly where most teams already are: coping in a normal month, and falling behind the moment volume spikes or a batch arrives with deviations attached.
The more workable model most mature quality functions land on is hybrid. A core in-house team holds day-to-day review, product knowledge, and the QP relationship. Outsourced reviewers are brought in for surge periods, specialist product types, or backlog recovery, working to the same procedures and reporting into the same QP sign-off. You get the continuity of an internal function without carrying fixed cost for capacity you only need some of the time.
This is not a compromise. It is how review capacity should be built in a function where demand is inherently uneven, and where the cost of being under-resourced at the wrong moment is measured in missed patient access, not just missed deadlines.
Getting ahead of the next batch
If your release timelines keep slipping and the manufacturing side of the business keeps coming back clean, the review stage is the place to look.
The question worth asking is not whether your team works hard enough. It almost certainly does. The question is whether the review capacity you have was ever sized for the batches you are actually releasing, or just for an average month that stopped being representative some time ago.